IL272123A - Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions - Google Patents

Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions

Info

Publication number
IL272123A
IL272123A IL272123A IL27212320A IL272123A IL 272123 A IL272123 A IL 272123A IL 272123 A IL272123 A IL 272123A IL 27212320 A IL27212320 A IL 27212320A IL 272123 A IL272123 A IL 272123A
Authority
IL
Israel
Prior art keywords
tilmanocept
99mtc
identifying
malignant tumors
therapeutic anti
Prior art date
Application number
IL272123A
Other languages
English (en)
Hebrew (he)
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of IL272123A publication Critical patent/IL272123A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicinal Preparation (AREA)
IL272123A 2017-07-21 2020-01-19 Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions IL272123A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762535752P 2017-07-21 2017-07-21
PCT/US2018/043176 WO2019018815A1 (en) 2017-07-21 2018-07-20 USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Publications (1)

Publication Number Publication Date
IL272123A true IL272123A (en) 2020-03-31

Family

ID=65014640

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272123A IL272123A (en) 2017-07-21 2020-01-19 Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions

Country Status (7)

Country Link
US (1) US20190022259A1 (cg-RX-API-DMAC7.html)
EP (1) EP3655107A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020528059A (cg-RX-API-DMAC7.html)
CN (1) CN111447955A (cg-RX-API-DMAC7.html)
CA (1) CA3070494A1 (cg-RX-API-DMAC7.html)
IL (1) IL272123A (cg-RX-API-DMAC7.html)
WO (1) WO2019018815A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021008879A (es) * 2019-01-25 2021-08-19 Navidea Biopharmaceuticals Inc Composiciones y metodos para evaluar la patologia mediada por macrofagos.
US20210052639A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
WO2021067479A1 (en) * 2019-09-30 2021-04-08 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
US11859023B2 (en) * 2020-07-08 2024-01-02 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
EP4472643A1 (en) 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671256A (en) * 1984-05-25 1987-06-09 Lemelson Jerome H Medical scanning, monitoring and treatment system and method
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
JP2005226021A (ja) * 2004-02-16 2005-08-25 Nihon Medi Physics Co Ltd マンノース受容体親和性化合物
HK1225623A1 (zh) * 2013-07-22 2017-09-15 纳维迪亚生物制药有限公司 用於诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
US10806803B2 (en) * 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
US20170202969A1 (en) * 2014-07-17 2017-07-20 Larry Schlesinger Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
CA2974634A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
CA3039519A1 (en) * 2016-10-04 2018-04-12 Cardinal Health 414, Llc Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
IL265830B (en) * 2016-10-07 2022-07-01 Navidea Biopharmaceuticals Inc Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same
WO2018068060A1 (en) * 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections

Also Published As

Publication number Publication date
CN111447955A (zh) 2020-07-24
EP3655107A4 (en) 2021-04-28
JP2020528059A (ja) 2020-09-17
EP3655107A1 (en) 2020-05-27
WO2019018815A1 (en) 2019-01-24
CA3070494A1 (en) 2019-01-24
US20190022259A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
IL274246A (en) Methods for diagnosing and treating cancer
IL268396A (en) Diagnostic and therapeutic methods for cancer
IL271888A (en) Therapeutic and diagnostic methods for cancer
IL280707A (en) Diagnostic and therapeutic methods for the treatment of breast cancer
IL273071A (en) Treatment and diagnosis methods for cancer
IL265759A (en) Therapeutic and diagnostic methods for cancer
EP3806724A4 (en) DETECTION AND CHARACTERIZATION OF CANCERUS TUMORS
HUE051815T2 (hu) Terápiás és diagnosztikai eljárások rákra
IL255372A0 (en) Therapeutic and diagnostic methods for cancer
IL262208A (en) Diagnostic and therapeutic methods for cancer
CA185208S (en) Medical probe
AU201714303S (en) Diagnostic instruments and apparatus
HUE040066T2 (hu) Eljárások és felszerelések tumorok molekuláris szubtipizálásához
GB201707550D0 (en) Cancer treatment - proton tomography apparatus and method of use thereof
GB201814350D0 (en) Diagnosis of cancer
IL276089A (en) Methods for colon cancer detection and treatment monitoring
EP3655107A4 (en) Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions
IL253582B (en) Detection and treatment of malignant tumours in the cns
IL255104A0 (en) MRI thermography for cardiac injury assessment
IL272810A (en) Methods for diagnosing and treating lung cancer
IL284237A (en) Imaging and treatment of tumors expressing somastatin receptor
GB201820994D0 (en) Methods of treatment and diagnosis of tumours
PL3857230T3 (pl) Sposoby diagnostyczne dla potrójnie ujemnego raka piersi
EP3740755C0 (en) USE OF THE TAS1R3 PROTEIN AS A MARKER FOR THERAPEUTIC, DIAGNOSTIC AND/OR PROGNOSTIC PURPOSES FOR TUMORS EXPRESSING THIS PROTEIN
IL271309A (en) Methods of treating brain tumors using combination therapy